Skip to main content

Table 3 Tumor response (immune related - irRC)

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Response

All patients

n = 30

No. of pts. (%)

irBOR

 irCR

1 (3)

 irPR

7 (23)

 irSD

9 (30)

 irPD

13 (43)

 irDCR

17 (57)

 irCBR

13 (43)

 irBORR

8 (27)

  1. ir immune related, BOR best overall response, CR complete response, PR partial response, SD stable disease, PD progressive disease, BORR best overall response rate, DCR disease control rate (CR + PR + SD), CBR clinical benefit rate (CR + PR + SD ≥ 24 weeks)